-
1
-
-
77952542701
-
Multidrug-resistant and extensively drug-resistant tuberculosis: A threat to global control of tuberculosis
-
Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010;375:1830-43.
-
(2010)
Lancet
, vol.375
, pp. 1830-1843
-
-
Gandhi, N.R.1
Nunn, P.2
Dheda, K.3
-
4
-
-
84902185616
-
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: A TBNET consensus statement
-
Lange C, Abubakar I, Alffenaar J, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014;44:23-63.
-
(2014)
Eur Respir J
, vol.44
, pp. 23-63
-
-
Lange, C.1
Abubakar, I.2
Alffenaar, J.3
-
6
-
-
77955872446
-
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis
-
Caminero JA, Sotgiu G, Zumla A, et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010;10:621-9.
-
(2010)
Lancet Infect Dis
, vol.10
, pp. 621-629
-
-
Caminero, J.A.1
Sotgiu, G.2
Zumla, A.3
-
7
-
-
84867754043
-
Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: A prospective cohort study
-
Dalton T, Cegielski P, Akksilp S, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012;380:1406-17.
-
(2012)
Lancet
, vol.380
, pp. 1406-1417
-
-
Dalton, T.1
Cegielski, P.2
Akksilp, S.3
-
8
-
-
0028274105
-
The effect of directly observed therapy on rates of drug resistance and relapse in tuberculosis
-
Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994;330:179-84.
-
(1994)
N Engl J Med
, vol.330
, pp. 179-184
-
-
Weis, S.E.1
Slocum, P.C.2
Blais, F.X.3
-
9
-
-
79955610445
-
Managing a case of extensively drug-resistant (XDR) pulmonary tuberculosis
-
Phua CK, Chee CBE, Chua APG, et al. Managing a case of extensively drug-resistant (XDR) pulmonary tuberculosis in Singapore. Ann Acad Med Singapore 2011;40:132-5.
-
(2011)
Singapore. Ann Acad Med Singapore
, vol.40
, pp. 132-135
-
-
Cbe, P.1
Chee, C.K.2
Apg, C.3
-
10
-
-
10044273203
-
Adverse events in the treatment of multidrug-resistant tuberculosis: Results from the DOTS-Plus initiative
-
Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004;8:1382-4.
-
(2004)
Int J Tuberc Lung Dis
, vol.8
, pp. 1382-1384
-
-
Nathanson, E.1
Gupta, R.2
Huamani, P.3
-
11
-
-
84875699280
-
Serious treatment related adverse drug reaction among anti-retroviral naive MDR-TB patients
-
Van der Walt M, Lancaster J, Odendaal R, et al. Serious treatment related adverse drug reaction among anti-retroviral naive MDR-TB patients. PLoS ONE 2013;8: e58817.
-
(2013)
PLoS ONE
, vol.8
, pp. 58817
-
-
Van Der Walt, M.1
Lancaster, J.2
Odendaal, R.3
-
12
-
-
80053067126
-
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
-
Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011;38:516-28.
-
(2011)
Eur Respir J
, vol.38
, pp. 516-528
-
-
Falzon, D.1
Jaramillo, E.2
Schünemann, H.J.3
-
13
-
-
84880158505
-
Drug resistance beyond extensively drug-resistant tuberculosis: Individual patient data meta-analysis
-
Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013;42:169-79.
-
(2013)
Eur Respir J
, vol.42
, pp. 169-179
-
-
Migliori, G.B.1
Sotgiu, G.2
Gandhi, N.R.3
-
14
-
-
70349141401
-
Treatment outcome of multi-drug resistant tuberculosis: A systematic review and meta-analysis
-
Johnston JC, Shahidi NC, Sadatsafavi M, et al. Treatment outcome of multi-drug resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE 2009;4: e6914.
-
(2009)
PLoS ONE
, vol.4
, pp. 6914
-
-
Johnston, J.C.1
Shahidi, N.C.2
Sadatsafavi, M.3
-
15
-
-
33847382372
-
Outcome of pulmonary multidrug-resistant tuberculosis: A 6-year follow-up study
-
Chiang CY, Enarson DA, Yu MC, et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-year follow-up study. Eur Respir J 2006;28:980-5.
-
(2006)
Eur Respir J
, vol.28
, pp. 980-985
-
-
Chiang, C.Y.1
Enarson, D.A.2
Yu, M.C.3
-
16
-
-
84880162469
-
Resistance of fluoroquinolones and second-line injectable drugs: Impact on multi-drug resistant TB outcomes
-
Falzon D, Gandhi N, Migliori GB, et al. Resistance of fluoroquinolones and second-line injectable drugs: impact on multi-drug resistant TB outcomes. Eur Respir J 2013;42:156-68.
-
(2013)
Eur Respir J
, vol.42
, pp. 156-168
-
-
Falzon, D.1
Gandhi, N.2
Migliori, G.B.3
-
18
-
-
19944429772
-
A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis
-
Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307:223-7.
-
(2005)
Science
, vol.307
, pp. 223-227
-
-
Andries, K.1
Verhasselt, P.2
Guillemont, J.3
-
19
-
-
54449084104
-
Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis
-
Koul A, Vranckx L, Dendouga N, et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 2008;283:25273-80.
-
(2008)
J Biol Chem
, vol.283
, pp. 25273-25280
-
-
Koul, A.1
Vranckx, L.2
Dendouga, N.3
-
20
-
-
62949223223
-
Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue
-
Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother 2009;53:1290-2.
-
(2009)
Antimicrob Agents Chemother
, vol.53
, pp. 1290-1292
-
-
Haagsma, A.C.1
Abdillahi-Ibrahim, R.2
Wagner, M.J.3
-
21
-
-
84924420073
-
Compassionate use of Bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: Interim analysis of a French cohort
-
Guglielmetti L, Le Du D, Jachym M, et al. Compassionate use of Bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 2015;60:188-94.
-
(2015)
Clin Infect Dis
, vol.60
, pp. 188-194
-
-
Guglielmetti, L.1
Le Du, D.2
Jachym, M.3
-
22
-
-
84907377122
-
Multidrug-resistant tuberculosis and culture conversion with Bedaquiline
-
Diacon AH, Pym A, Grobusch MP et al. Multidrug-resistant tuberculosis and culture conversion with Bedaquiline. N Engl J Med 2014;371:723-32.
-
(2014)
N Engl J Med
, vol.371
, pp. 723-732
-
-
Diacon, A.H.1
Pym, A.2
Grobusch, M.P.3
-
23
-
-
84872131305
-
Approval of novel TB drug celebrated-with restraint
-
Cohen J. Approval of novel TB drug celebrated-with restraint. Science 2013;339:130.
-
(2013)
Science
, vol.339
, pp. 130
-
-
Cohen, J.1
-
25
-
-
84944083235
-
-
Compassionate Use Programme of TMC207 in patients with Extensively Drug Resistant(XDR) or Pre-XDR Mycobacterium tuberculosis (MTB) Pulmonary Infection To access, contact RA-CNTNL-JANSSENCU@ITS.JNJ.COM
-
Compassionate Use Programme of TMC207 in patients with Extensively Drug Resistant(XDR) or Pre-XDR Mycobacterium tuberculosis (MTB) Pulmonary Infection. Guidelines for Physicians and Pharmacists. To access, contact RA-CNTNL-JANSSENCU@ITS.JNJ.COM.
-
Guidelines for Physicians and Pharmacists
-
-
-
26
-
-
84944083236
-
-
Use of New TB Drugs (accessed 6 Jul 2013)
-
Challenges for Compassionate Use of New TB Drugs. http://www.resisttb.org/?page-id=1371 (accessed 6 Jul 2013).
-
Challenges for Compassionate
-
-
-
27
-
-
84861140844
-
Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: Long-term outcome, tolerability, and effect on emergence of drug resistance
-
Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012;56:3271-6.
-
(2012)
Antimicrob Agents Chemother
, vol.56
, pp. 3271-3276
-
-
Diacon, A.H.1
Donald, P.R.2
Pym, A.3
-
28
-
-
66649090346
-
The diarylquinoline TMC207 for multidrug-resistant tuberculosis
-
Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360:2397-405.
-
(2009)
N Engl J Med
, vol.360
, pp. 2397-2405
-
-
Diacon, A.H.1
Pym, A.2
Grobusch, M.3
-
29
-
-
84875639613
-
Approval of a tuberculosis drug based on a paradoxical surrogate measure
-
Avorn J. Approval of a tuberculosis drug based on a paradoxical surrogate measure. JAMA 2013;309:1349-50.
-
(2013)
JAMA
, vol.309
, pp. 1349-1350
-
-
Avorn, J.1
-
30
-
-
84944083237
-
-
Sirturo (bedaquiline) [product information]. Titusville, NJ: Janssen Therapeutics
-
Sirturo (bedaquiline) [product information]. Titusville, NJ: Janssen Therapeutics, 2012.
-
(2012)
-
-
-
31
-
-
84898619017
-
Cross resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis
-
Hartkoorn RC, Uplekar S, Cole ST. Cross resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014;58:2979-81.
-
(2014)
Antimicrob Agents Chemother
, vol.58
, pp. 2979-2981
-
-
Hartkoorn, R.C.1
Uplekar, S.2
Cole, S.T.3
-
32
-
-
84904255286
-
Acquired resistance of Mycobacterium tuberculosis to bedaquiline
-
Andries K, Villellas C, Coeck N, et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS ONE 2014;9:e102135.
-
(2014)
PLoS ONE
, vol.9
, pp. 102135
-
-
Andries, K.1
Villellas, C.2
Coeck, N.3
-
33
-
-
84891942518
-
Bedaquiline in MDR/XDR-TB cases: First experience on compassionate use
-
Tiberi S, De Lorenzo S, Centis R, et al. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J 2014;43:289-92.
-
(2014)
Eur Respir J
, vol.43
, pp. 289-292
-
-
Tiberi, S.1
De Lorenzo, S.2
Centis, R.3
-
34
-
-
84922202908
-
A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment
-
Somoskovi A, Bruderer V, Hömke R, et al. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir J 2015;45:554-5.
-
(2015)
Eur Respir J
, vol.45
, pp. 554-555
-
-
Somoskovi, A.1
Bruderer, V.2
Hömke, R.3
|